Inspire Medical Systems, Inc. Announces Issuance of Positive Assessment for Inspire Therapy by Blue Cross Blue Shield Association’s Evidence Street
January 07, 2019 at 08:00 am
Share
Inspire Medical Systems, Inc. announced that the Blue Cross Blue Shield Association's (“BCBSA”) Evidence Street issued a positive assessment of Inspire therapy to its members. BCBSA is a national federation of 36 Blue Cross and Blue Shield (“BCBS”) companies that, when combined, is one of the leading health associations in the U.S. The report summarized that sufficient evidence exists to determine that hypoglossal nerve stimulation results in a meaningful improvement in the net health outcome for patients meeting the following selection criteria, which are based on information from clinical study populations and clinical expert opinion: age = 22 years in adults, or adolescents with Down’s syndrome (age 10 to 21 years); and diagnosed moderate to severe OSA (with less than 25% central apneas); and CPAP failure or inability to tolerate CPAP; and body mass index = 35 kg/m2 in adults; and favorable pattern of palatal collapse. The BCBSA’s Evidence Street platform provides health care decision-makers easy access to impartial medical evidence reviews for devices, diagnostics and pharmaceuticals and was created to make BCBSA’s evidence review process of medical technologies and therapies more transparent, efficient and comprehensive. BCBSA collects and analyzes available peer-reviewed evidence, then synthesizes that data and ascertains if the evidence is sufficient or insufficient to determine the effect on health outcomes. The BCBSA’s Evidence Street does not determine whether each of the 36 BCBS companies nationwide cover a medical technology. However, it provides BCBS companies with evidence-based opinions that the BCBS companies often consider in their decisions.
Inspire Medical Systems, Inc. is a medical technology company. The Company is focused on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire system is the FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The Company has developed a novel, closed-loop solution that continuously monitors a patientâs breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sell its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ENT physicians and sleep centers.
INSPIRE MEDICAL SYSTEMS, INC. 
